TRCT
SLN

Tower Research Capital (TRC)’s Silence Therapeutics SLN Stock Holding History

Tower Research Capital (TRC)’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Sell
1,639
-674
-29% -$4.74K ﹤0.01% 3651
2026
Q1 		$12.2K Sell
2,313
-135
-6% -$743 ﹤0.01% 3806
2025
Q4 		$14.9K Buy
2,448
+1
+0% +$6 ﹤0.01% 3325
2025
Q3 		$12.7K Buy
2,447
+19
+0.8% +$106 ﹤0.01% 3759
2025
Q2 		$14.1K Buy
2,428
+61
+3% +$262 ﹤0.01% 3851
2025
Q1 		$6.67K Buy
2,367
+1,735
+275% +$8.47K ﹤0.01% 4023
2024
Q4 		$4.35K Buy
+632
New +$8.15K ﹤0.01% 4476
2024
Q1 		– Sell
-707
Closed -$12.3K – 6118
2023
Q4 		$12.3K Buy
+707
New +$7.94K ﹤0.01% 4057
2023
Q3 		– Sell
-800
Closed -$4.4K – 6194
2023
Q2 		$4.4K Buy
+800
New +$4.83K ﹤0.01% 4953
2022
Q3 		– Sell
-120
Closed -$1K – 6442
2022
Q2 		$1K Buy
120
+3
+3% +$36 ﹤0.01% 5850
2022
Q1 		$2K Buy
+117
New +$2.33K ﹤0.01% 5594

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Tower Research Capital (TRC)'s SLN Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Silence Therapeutics (SLN) stake by 29% in Q2 2026, selling an estimated $4.74K and leaving 1,639 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #3651.

Tower Research Capital (TRC) first reported a position in SLN in Q1 2022 and has held it in 11 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Tower Research Capital (TRC) held 1,639 shares of Silence Therapeutics worth $18K as of Q2 2026.
  • Tower Research Capital (TRC) sold 674 Silence Therapeutics shares in Q2 2026, an estimated $4.74K.
  • Silence Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3651 holding.
  • Tower Research Capital (TRC) first reported a position in Silence Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.